Noveris Announces Conversion Of Debentures; Filing Of Early Warning Reports By JJK Holdings Ltd. And Joshua Bartch

Core Viewpoint - Noveris Health Sciences Inc. has announced the conversion of debentures totaling $8,188,628 into 47,687,939 common shares, initiated by the debenture holders [1][2]. Group 1: Debenture Conversion Details - The debentures converted at a price of $0.192682432, which is based on the 20-day trailing volume-weighted average trading price of the Company's common shares as of the conversion date [2]. - JJK Holdings Ltd. converted a debenture worth $7,878,792 into 40,890,039 common shares, with the debenture having been transferred to 23 parties prior to conversion [3]. - CEO Joshua Bartch converted his debenture of $1,309,836 into 6,797,900 common shares, increasing his total holdings to 6,827,419 shares, representing 13.95% of the Company's issued shares [4][6]. Group 2: Shareholder Information - Following the conversion, JJK, through its subsidiary, holds 3,848,706 common shares, which is 7.86% of the Company's issued shares [4]. - Prior to the conversion, the Company had 1,235,061 common shares outstanding, and the conversion of the JJK Debenture could have resulted in a significant increase in shares held by JJK [4]. - Mr. Bartch's conversion of his debenture could have resulted in a larger percentage of ownership had the conversion price been different [6]. Group 3: Company Overview - Noveris Health Sciences Inc. is focused on developing innovative medications and therapies for mental health disorders, including nicotine addiction and PTSD [9]. - The Company aims to blend advanced technology with a robust infrastructure for drug discovery and development, aspiring to accelerate the development of breakthrough medications [9]. - Noveris is also concentrating on the next generation of psychedelic medicine, creating innovative compounds with significant therapeutic potential [9].